Ironwood Pharmaceuticals INC Form 4 insider transactions

Alexander J. Denner, a Director and 10% owner of Ironwood Pharmaceuticals Inc. (IRWD), has reported the acquisition of 24,193 shares of Class A Common Stock as part of the company's non-employee director compensation policy.

Ironwood Pharmaceuticals Director Marla Kessler was granted 45,000 shares of Class A Common Stock as part of the company's non-employee director compensation policy.

Ironwood Pharmaceuticals Inc. Director Catherine Moukheibir was granted 45,000 shares of Class A Common Stock as part of her compensation, increasing her direct beneficial ownership to 117,944 shares.

Ironwood Pharmaceuticals, Inc. Director Jay Shepard has reported the acquisition of 45,000 shares of Class A Common Stock as a restricted stock grant, increasing his total beneficial ownership to 171,555 shares.

Ironwood Pharmaceuticals, Inc. Director Jon R. Duane has acquired 45,000 shares of Class A Common Stock as a restricted stock grant, increasing his direct beneficial ownership to 190,339 shares.

Ironwood Pharmaceuticals, Inc. Director Mark Currie was granted 45,000 shares of Class A Common Stock as part of the company's non-employee director compensation policy.

Ironwood Pharmaceuticals Inc. director Julie McHugh was granted 45,000 shares of Class A Common Stock as part of the company's non-employee director compensation policy.

Ironwood Pharmaceuticals Director Andrew Dreyfus reported the acquisition of 45,000 restricted Class A common stock shares as part of his compensation, alongside a transfer of 4,917 shares to an ex-spouse, resulting in a total beneficial ownership of 228,313 shares.

Alexander J. Denner, a Director and 10% owner of Ironwood Pharmaceuticals Inc., acquired 45,000 shares of Class A Common Stock through a restricted stock grant, increasing his direct beneficial ownership.

CEO Thomas McCourt reports the sale of shares to cover tax obligations and acquisition of restricted stock units.

Tammi L. Gaskins, Chief Commercial Officer of Ironwood Pharmaceuticals, sold 2,563 shares of Class A Common Stock to cover tax withholding obligations related to vesting restricted stock units.

Alexander Denner, a director and 10% owner of Ironwood Pharmaceuticals, reported changes in beneficial ownership of Class A Common Stock, including acquisitions and disposals.

Ironwood Pharmaceuticals CEO Thomas McCourt sold shares to cover tax withholding obligations related to the vesting of restricted stock units and performance-based restricted stock units.

Ronald Silver, Principal Accounting Officer of Ironwood Pharmaceuticals, sold 12,048 shares of Class A Common Stock to cover tax withholding obligations related to vesting restricted stock units.

Michael Shetzline, SVP, CMO, Head-Res&Drug at Ironwood Pharmaceuticals, sold shares to cover tax withholding obligations related to vesting restricted stock units.

John Minardo, Chief Legal Officer of Ironwood Pharmaceuticals, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Gregory S. Martini, CFO of Ironwood Pharmaceuticals, sold 12,052 shares of Class A Common Stock on February 10, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Ronald Silver, Principal Accounting Officer at Ironwood Pharmaceuticals, reports changes in beneficial ownership of Class A Common Stock, including acquisition and disposal of shares.

Gregory S. Martini, CFO of Ironwood Pharmaceuticals, reported the acquisition of restricted stock units and subsequent beneficial ownership of Class A Common Stock.

Michael Shetzline, SVP, CMO, Head-Res&Drug at Ironwood Pharmaceuticals, acquired 48,224 shares of Class A Common Stock on January 17, 2025, following the vesting of performance-based restricted stock units.

Ironwood Pharmaceuticals' Chief Legal Officer, John Minardo, acquired 40,187 shares of Class A Common Stock on January 17, 2025, through the vesting of performance-based restricted stock units.

Ironwood Pharmaceuticals CEO, Thomas A. McCourt, acquired shares through performance-based restricted stock units and the employee stock purchase plan.

Alexander Denner, a director and 10% owner of Ironwood Pharmaceuticals, reported changes in beneficial ownership of Class A Common Stock, including the acquisition of shares and indirect ownership through Sarissa Capital Management LP.

An Ironwood Pharmaceuticals executive sold 5,360 shares of Class A Common Stock to cover tax obligations related to vesting restricted stock units.

An Ironwood Pharmaceuticals executive sold 11,001 shares of Class A Common Stock to cover tax obligations related to vesting restricted stock units.

Alexander Denner, a director and 10% owner of Ironwood Pharmaceuticals, reported acquiring shares and indirect beneficial ownership through Sarissa Capital Management.

John Minardo, Chief Legal Officer of Ironwood Pharmaceuticals, sold 9,910 shares of Class A Common Stock on August 12, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Ronald Silver, Principal Accounting Officer of Ironwood Pharmaceuticals, sold 3,107 shares of Class A Common Stock to cover tax withholding obligations related to vesting restricted stock units.

Director Jay Shepard reports acquisition of Ironwood Pharmaceuticals shares as part of a non-employee director compensation policy.

Director Andrew Dreyfus reports a transaction involving Ironwood Pharmaceuticals Class A Common Stock, including the acquisition of shares and a transfer related to a domestic relations order.